1. Home
  2. TKLF vs IMNN Comparison

TKLF vs IMNN Comparison

Compare TKLF & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yoshitsu Co. Ltd

TKLF

Yoshitsu Co. Ltd

HOLD

Current Price

$2.08

Market Cap

10.1M

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$2.96

Market Cap

11.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKLF
IMNN
Founded
2006
1982
Country
Japan
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
11.0M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
TKLF
IMNN
Price
$2.08
$2.96
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
15.4K
57.5K
Earning Date
12-19-2025
03-31-2026
Dividend Yield
11.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.03
$0.37
52 Week High
$4.32
$9.32

Technical Indicators

Market Signals
Indicator
TKLF
IMNN
Relative Strength Index (RSI) 32.36 45.22
Support Level $2.10 $2.52
Resistance Level $3.09 $3.61
Average True Range (ATR) 0.15 0.23
MACD -0.03 0.01
Stochastic Oscillator 11.30 58.54

Price Performance

Historical Comparison
TKLF
IMNN

About TKLF Yoshitsu Co. Ltd

Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: